Table 3.
Changes of metabolic parameters at week 12 and week 24 after interleukin-17A blockade (secukinumab/Cosentyx®) stratified by PASI-90 response at week 24.
| Week | All N = 99 |
PASI-90+ at week 24 n = 39 |
PASI-90– at week 24 n = 60 |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 0 | Week 12 | Week 24 | Week 0 | Week 12 | Week 24 | Week 0 | Week 12 | Week 24 | |
| BW | 80.33 | 81.12* | 81.32* | 74.40 | 75.66 | 75.76 | 84.18 | 84.66 | 84.94 |
| BMI | 28.92 | 29.19* | 29.27* | 27.24 | 27.68 | 27.87 | 30.00 | 30.17 | 30.26 |
| hs-CRP+ | 3.7 | 2.2** | 2.5* | 2.3 | 1.7* | 1.8* | 4.4 | 3.0* | 3.6 |
| ESR+ | 9 | 7 | 8 | 9 | 7 | 7 | 9 | 8 | 8 |
| Sugar | 98 | 103* | 102 | 101 | 102 | 103 | 97 | 104* | 101 |
| UA | 6.6 | 6.3* | 6.4* | 6.1 | 5.9 | 6.1 | 6.9 | 6.5 | 6.5* |
| HDL | 44 | 44 | 44 | 46 | 46 | 47 | 43 | 42 | 43 |
| LDL | 114 | 115 | 113 | 114 | 113 | 113 | 113 | 115 | 113 |
| CHOL | 185 | 188 | 188 | 184 | 187 | 190 | 185 | 189 | 186 |
| TG | 134 | 152* | 152* | 129 | 138 | 141 | 137 | 160* | 159* |
| n-HDL | 141 | 145 | 144 | 140 | 141 | 144 | 142 | 147 | 144 |
| AIP | 0.45 | 0.50* | 0.50* | 0.41 | 0.42 | 0.43 | 0.47 | 0.54* | 0.54* |
Mean, +median.
The paired t-test was used to analyze metabolic parameters (1) between week 0 and week 12, (2) between week 0 and week 24. Wilcoxon signed rank test was used to analyze the ESR and hs-CRP (1) between week 0 and week 12, (2) between week 0 and week 24.
p value was less than 0.05.
p value was less than 0.001.
AIP, Atherogenic index of plasma (AIP = log(TG/HDL cholesterol); BMI, body mass index; BW, Body weight; CHOL, cholesterol; ESR, erythrocyte sedimentation rate; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; n-HDL, non high-density lipoprotein; PASI, Psoriasis Area and Severity Index; TG, triglyceride; UA, uric acid